Boston's biotech sector is facing challenges, with companies struggling amid a slump in the industry. Despite hopes for a turnaround in 2025, falling stock...
Novo Nordisk’s Obesity Trial Disappoints
Novo Nordisk, a key player in the pharmaceutical industry, recently faced a setback with their next-generation obesity candidate, CagriSema. The...